No. Colossal Biosciences is private and has not filed to go public. There is no S-1 on file.
What is Colossal Biosciences' valuation in 2026?
Colossal Biosciences is valued at $10B as of 2025-Q3, set by its Series C extension ($120M, Sep 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Colossal Biosciences filed an S-1?
No public S-1 is on file for Colossal Biosciences.
Who are Colossal Biosciences' investors?
Colossal Biosciences' investors include TWG Global, USIT, Robert Nelsen, Bob Iger, Tim Draper, Tom Brady and 5 more.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Colossal Biosciences is a Dallas-based gene-editing company on a mission to revive extinct species, with active programs targeting the woolly mammoth, Tasmanian tiger (thylacine), and dodo bird. Co-founded by serial entrepreneur Ben Lamm and Harvard geneticist George Church, the company reached a $10.2B valuation in January 2025 with a $200M Series C led by TWG Global, becoming Texas's first decacorn. A $120M Series C extension followed in September 2025 with continued progress on avian de-extinction.
Company Profile
CEO
Ben Lamm
Founded
2021
HQ
Dallas, Texas
Employees
~200
Total Raised
$557.6M
Growth
Texas's first decacorn; $10.2B Series C valuation
Last Round
Series C extension — $120M (Sep 2025)
IPO Status
Private
Fundraising Status
Series C extension · $120M · 11 mo ago
PrivateTotal raised $557.6M
Secondary Market
Implied price / share
$8.5
Last round price / share
$24.89
vs last round
-65.8%
Open interest
3
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C extension
$120M
Sep 2025
—
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Colossal Biosciences — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-08-19. Re-checked weekly.
Talent Signal
Hiring trend
▲ Hiring uptrend
57% of roles posted in last 30d
Open roles
7
via greenhouse
Product-build share
86%
engineering, research, product, design
Trajectory
expanding
heavy product build — 86% of open roles are product-building functions (engineering/research/product) — 4 of 7 open roles are research.
No tracked executive churn; open roles trending up.
Counted from Colossal Biosciences's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Ben LammGeorge Church
Investors
TWG Global · USIT · Robert Nelsen · Bob Iger · Tim Draper · Tom Brady · Paris Hilton · Animoca Brands · In-Q-Tel · Breyer Capital · Thomas Tull
Products
Woolly mammoth revival program
Tasmanian tiger (thylacine) revival
Dodo bird revival
Spinoff: Form Bio (computational biology)
Spinoff: Breaking (plastic-degrading enzymes)
Competitors
Ginkgo Bioworks · Twist Bioscience · Editas Medicine · Genus plc
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q3. Refreshed quarterly.